ResearchingRefreshing REGN from the latest filings.
1 of 8 sections ready
As of Sep 6, 2026, 2:26 PM
Price Chart
Overview
Regeneron is a biotechnology company that discovers, develops, manufactures, and sells medicines mainly for immune diseases, eye diseases, and cancer, using proprietary antibody-engineering and genetics platforms. Its most important growth product is Dupixent, an immune-disease medicine developed with Sanofi that is already marketed globally and continues to gain new uses, while EYLEA HD remains a major marketed eye-care product and Libtayo is the main marketed cancer product. Regeneron makes money from its own product sales and from its share of Sanofi collaboration profits; for the three months ended June 30, 2026, revenue was $4.3 billion, global Dupixent sales were $6.0 billion, U.S. EYLEA HD sales were $596 million, and Libtayo sales were $489 million.
The opportunity is a highly profitable commercial base led by rapidly growing Dupixent, improving EYLEA HD adoption, and a pipeline that includes cemdisiran, whose applications for generalized myasthenia gravis were accepted for review as of the quarter ended June 30, 2026. The key risk is concentration in EYLEA/EYLEA HD and Dupixent, making earnings vulnerable to eye-drug competition, pricing pressure, patent or manufacturing setbacks, and any failure of pipeline programs to replace mature-product erosion.